1. 1609 Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170). (September 2015) Authors: Pinter, T.; Morrow, P.K.; Cesas, A.; Croitoru, A.; Decaestecker, J.; Gibbs, P.; Hotko, Y.; Jassem, J.; Kurteva, G.; Novotny, J.; O'Reilly, S.; Salek, T.; Khosrowshahi, L.; Reiner, M.; Klippel, Z.; Blanke, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2007 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. (September 2015) Authors: Innocenti, F.; Owzar, K.; Chen, J.; Sibley, A.; Niedzwiecki, D.; Bertagnolli, M.; Friedman, P.; Furukawa, Y.; Kubo, M.; Ratain, M.; Blanke, C.; Heinz-Josef, L.; Venook, A.; McLeod, H. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗